Expert guides on testosterone therapy, hormone optimization, and advanced men's health protocols from leading specialists.
Tirzepatide vs semaglutide — head-to-head comparison for men. Weight loss results, side effects, cost, and how to find a GLP-1 provider near you.
BPC-157Yes, BPC-157 can be taken orally and research suggests it remains stable in gastric acid, making oral administration a viable alternative to injectable forms for many therapeutic applications, though bioavailability may differ between routes.
TesamorelinTesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce natural growth hormone, which then reduces visceral fat by enhancing lipolysis and fat metabolism, particularly in patients with HIV-associated lipodystrophy.
OzempicOzempic (semaglutide) does not directly damage kidneys, but can cause acute kidney injury in rare cases, primarily through dehydration from gastrointestinal side effects. Clinical trials show potential long-term kidney protective benefits for diabetic patients, though monitoring is essential for those with pre-existing kidney conditions.
OzempicYes, Ozempic (semaglutide) has been associated with an increased risk of acute pancreatitis, though the overall risk remains relatively low. Clinical studies and post-market surveillance have identified pancreatitis as a potential side effect, occurring in approximately 0.2-1% of patients taking GLP-1 receptor agonists.
SemaglutideCurrent research shows mixed evidence on whether semaglutide causes depression. While some studies suggest a potential link to mood changes in certain individuals, large-scale clinical trials have not established a definitive causal relationship between semaglutide and depression.
SemaglutideYes, semaglutide can cause headaches as a documented side effect. Clinical trials show headaches occur in 5-14% of patients, typically during the initial weeks of treatment as the body adjusts to the medication.
TirzepatideTirzepatide does not directly cause hair loss, but rapid weight loss associated with the medication can trigger telogen effluvium, a temporary form of hair shedding that typically occurs 2-4 months after significant weight reduction and usually resolves within 6-9 months.
OzempicCurrent evidence from clinical trials involving over 16,800 patients shows no increased cancer risk from Ozempic in humans. However, the medication carries a black box warning due to thyroid C-cell tumors observed in rodent studies, and it's contraindicated for patients with a personal or family history of medullary thyroid carcinoma.
SemaglutideSemaglutide can be associated with hair loss, though it's not a primary side effect listed in initial clinical trials. The hair loss is typically temporary and linked to rapid weight loss, nutritional deficiencies, and metabolic stress rather than a direct drug effect.
PeptidesPeptides can be beneficial when used appropriately, as they occur naturally in foods and our bodies, supporting various functions like muscle repair, skin health, and immune function. However, synthetic peptide supplements require medical supervision due to potential side effects and limited long-term safety data.
OzempicCurrent evidence suggests Ozempic does not directly cause depression in most patients, though some post-marketing reports have raised concerns. Clinical trials show no significant increased risk, but individual responses vary and mental health monitoring is recommended during treatment.
